Alexandra Keller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandra Keller has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Eberhard Keller
3 shared publicationsRoland Pfäffle
Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig (Direktor: Prof. Dr. med. W. Kiess)
2 shared publications- Wieland Kiess
LIFE Leipzig Research Center for Civilization Diseases, Leipzig University, 04103 Leipzig, Germany
2 shared publications Astrid Kniess
1 shared publicationChristian J Strasburger
1 shared publicationE. Keller
1 shared publication
Latest Publications
- 1 June 2007
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 156 (6) , 647-653
Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration
Objective: Pharmacokinetic and pharmacodynamic data after recombinant human GH (rhGH) administration in adults are scarce, but necessary to optimize replacement therapy and to detect doping. We examined pharmacokinetics, pharmacodynamics, and 20 kDa GH after injection of rhGH at different doses and routes of administration. Design: Open-label crossover study with single boluses of rhGH. Methods: Healthy trained subjects (10 males, 10 females) received bolus injections of rhGH on three occasions: 0.033 mg/kg s.c., 0.083 mg/kg s.c., and 0.033 mg/kg i.m. Concentrations of 22 and 20 kDa GH, IGF-I, and IGF-binding proteins (IGFBP)-3 were measured repeatedly before and up to 36 h after injection. Results: Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 μ g/l; AUC 196.2 and 123.8). Cmax and AUC were higher in males than in females (P < 0.01) and pharmacodynamic changes were more pronounced. IGFBP-3 concentrations showed no dose dependency. In response to rhGH administration, 20 kDa GH decreased in females and remained suppressed for 14–18 h (low dose) and 30 h (high dose). In males, 20 kDa GH was undetectable at baseline and throughout the study. Conclusions: After rhGH administration, pharmacokinetic parameters are mainly influenced by route of administration, whereas pharmacodynamic variables and 20 kDa GH concentrations are determined mainly by gender. These differences need to be considered for therapeutic use and for detection of rhGH doping.
- 1 June 2007
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 156 (6) , 647-653
Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration
Objective: Pharmacokinetic and pharmacodynamic data after recombinant human GH (rhGH) administration in adults are scarce, but necessary to optimize replacement therapy and to detect doping. We examined pharmacokinetics, pharmacodynamics, and 20 kDa GH after injection of rhGH at different doses and routes of administration. Design: Open-label crossover study with single boluses of rhGH. Methods: Healthy trained subjects (10 males, 10 females) received bolus injections of rhGH on three occasions: 0.033 mg/kg s.c., 0.083 mg/kg s.c., and 0.033 mg/kg i.m. Concentrations of 22 and 20 kDa GH, IGF-I, and IGF-binding proteins (IGFBP)-3 were measured repeatedly before and up to 36 h after injection. Results: Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 μ g/l; AUC 196.2 and 123.8). Cmax and AUC were higher in males than in females (P < 0.01) and pharmacodynamic changes were more pronounced. IGFBP-3 concentrations showed no dose dependency. In response to rhGH administration, 20 kDa GH decreased in females and remained suppressed for 14–18 h (low dose) and 30 h (high dose). In males, 20 kDa GH was undetectable at baseline and throughout the study. Conclusions: After rhGH administration, pharmacokinetic parameters are mainly influenced by route of administration, whereas pharmacodynamic variables and 20 kDa GH concentrations are determined mainly by gender. These differences need to be considered for therapeutic use and for detection of rhGH doping.
- 1 January 2007
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 20 (12) , 1307-1314
Administration of Arginine plus Growth Hormone Releasing Hormone to Evaluate Growth Hormone (GH) Secretory Status in Children with GH Deficiency
Diagnosis of growth hormone deficiency (GHD) in childhood is usually based on growth hormone (GH) response to at least two provocative stimuli. The aim of this study was to determine whether sequential administration of arginine (Arg) plus GH releasing hormone (GHRH) could be a useful tool in evaluating GHD in children. Thirty patients with short stature (mean age 9.0 years) with decreased growth rate were tested for GHD with Arg and the insulin tolerance test (ITT). Patients with confirmed GHD (peak GH <8 ng/ml) were subsequently tested with Arg + GHRH. Maximum GH stimulation for Arg and ITT was 6.3 (1.0-7.8) and 6.7 (0.5-7.7) ng/ml, respectively. Peak GH for the Arg + GHRH test was 36.3 (4.3-84.5) ng/ml and significantly different from the other provocative tests. Peak GH values for the three tests were not significantly correlated between tests or with clinical parameters. There were no significant differences in Arg + GHRH results between children with or without abnormal hypothalamic-pituitary MRI scans. Arg + GHRH gave higher GH levels than insulin or Arg alone. Because of the different causes of childhood GHD (hypothalamic and/or pituitary dysfunction), the Arg + GHRH test is unsuitable .for evaluating GHD and deciding whether GH replacement therapy is indicated.
- 1 January 2007
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 20 (12) , 1307-1314
Administration of Arginine plus Growth Hormone Releasing Hormone to Evaluate Growth Hormone (GH) Secretory Status in Children with GH Deficiency
Diagnosis of growth hormone deficiency (GHD) in childhood is usually based on growth hormone (GH) response to at least two provocative stimuli. The aim of this study was to determine whether sequential administration of arginine (Arg) plus GH releasing hormone (GHRH) could be a useful tool in evaluating GHD in children. Thirty patients with short stature (mean age 9.0 years) with decreased growth rate were tested for GHD with Arg and the insulin tolerance test (ITT). Patients with confirmed GHD (peak GH <8 ng/ml) were subsequently tested with Arg + GHRH. Maximum GH stimulation for Arg and ITT was 6.3 (1.0-7.8) and 6.7 (0.5-7.7) ng/ml, respectively. Peak GH for the Arg + GHRH test was 36.3 (4.3-84.5) ng/ml and significantly different from the other provocative tests. Peak GH values for the three tests were not significantly correlated between tests or with clinical parameters. There were no significant differences in Arg + GHRH results between children with or without abnormal hypothalamic-pituitary MRI scans. Arg + GHRH gave higher GH levels than insulin or Arg alone. Because of the different causes of childhood GHD (hypothalamic and/or pituitary dysfunction), the Arg + GHRH test is unsuitable .for evaluating GHD and deciding whether GH replacement therapy is indicated.
- 1 January 2007
- Published by Georg Thieme Verlag KG in Kinder- und Jugendmedizin
- Vol. 7 (03) , 145-152
Wachstum und Wachstumsstörung
Zusammenfassung: Eine Wachstumsstörung ist ein häufiges Symptom, das zu einer Vorstellung in der kinderärztlichen Betreuung führt. Dieses Symptom kann durch unterschiedliche Erkrankungen bedingt sein. Die manchmal erforderliche komplexe Diagnostik wird durch eine enge Kooperation von betreuenden Ärzten mit Betreuungs- und Fördereinrichtungen zielführend optimiert. Eine frühzeitige Diagnosestellung bei Vorliegen pathologischer Varianten eines Klein- oder Hochwuchses sowie eine entsprechende Betreuung sind wünschenswert.
- 1 January 2007
- Published by Georg Thieme Verlag KG in Kinder- und Jugendmedizin
- Vol. 7 (03) , 145-152
Wachstum und Wachstumsstörung
Zusammenfassung: Eine Wachstumsstörung ist ein häufiges Symptom, das zu einer Vorstellung in der kinderärztlichen Betreuung führt. Dieses Symptom kann durch unterschiedliche Erkrankungen bedingt sein. Die manchmal erforderliche komplexe Diagnostik wird durch eine enge Kooperation von betreuenden Ärzten mit Betreuungs- und Fördereinrichtungen zielführend optimiert. Eine frühzeitige Diagnosestellung bei Vorliegen pathologischer Varianten eines Klein- oder Hochwuchses sowie eine entsprechende Betreuung sind wünschenswert.
- 1 January 2007
- Published by Georg Thieme Verlag KG in Kinder- und Jugendmedizin
- Vol. 7 (04) , 209-216
Kleinwuchs
Zusammenfassung: Der Kleinwuchs eines Kindes ist ein häufiger Vorstellungsgrund in der pädiatrischen Praxis. Obwohl häufig eine Normvariante, ist die Abklärung eines Kleinwuchses oft komplex, da ein pathologischer Kleinwuchs viele Ursachen haben kann. Eine zu geringe Wachstumsrate oder eine verzögerte Entwicklung kann ein erstes Zeichen einer chronischen, schwerwiegenden Allgemeinerkrankung darstellen. Auch genetische Ursachen sind nicht selten. Eine frühzeitige Diagnostik der zugrunde liegenden Pathologie sowie die langfristige Betreuung des Patienten stellen eine Herausforderung für den behandelnden Kinderarzt und das spezialisierte Behandlungszentrum dar.
- 1 January 2007
- Published by Georg Thieme Verlag KG in Kinder- und Jugendmedizin
- Vol. 7 (04) , 209-216
Kleinwuchs
Zusammenfassung: Der Kleinwuchs eines Kindes ist ein häufiger Vorstellungsgrund in der pädiatrischen Praxis. Obwohl häufig eine Normvariante, ist die Abklärung eines Kleinwuchses oft komplex, da ein pathologischer Kleinwuchs viele Ursachen haben kann. Eine zu geringe Wachstumsrate oder eine verzögerte Entwicklung kann ein erstes Zeichen einer chronischen, schwerwiegenden Allgemeinerkrankung darstellen. Auch genetische Ursachen sind nicht selten. Eine frühzeitige Diagnostik der zugrunde liegenden Pathologie sowie die langfristige Betreuung des Patienten stellen eine Herausforderung für den behandelnden Kinderarzt und das spezialisierte Behandlungszentrum dar.